Erthang,
The original March 29, 2005 joint Abbott/BioCurex press release states, in one sentence, the below quote that is never qualified or limited in any way.
"Under terms of the agreement, Abbott obtains worldwide, semi-exclusive rights to commercialize products using BioCurex's RECAF technology."
It is not a false statement, but if the above quote is taken literally for what it says, Abbott obtained the worldwide, semi-exclusive right to commercialize any number of products, ranging from "A" to "Z" that utilize RECAF technology. Semi exclusive just means that other companies can obtain the rights from BioCurex to do the same thing. Worldwide is not important in what I am discussing here.
It is my humble opinion that, if BioCurex management is correct and BioCurex did, in fact, retain all rights to Histo-RECAF, tumor imaging, therapy, or vaccination, the press release should have read "Abbott obtains worldwide, semi-exclusive, limited rights to commercialize products using BioCurex's RECAF technology. "Limited" being the all important missing word. It would also be my humble opinion that Abbott's legal staff likely signed off on the press release to insure that none of Abbott's management would ever suffer later embarrassment if there was ever a stink about the press release. kag
News 
Market Data 
Discover 
